Cellectis SA (ADR) (CLLS) Reaches $26.46 After 5.00% Up Move, Revlon (REV) Sentiment Is 1.22

July 10, 2017 - By Nellie Frank

Revlon, Inc. manufactures, markets and sells around the world a range of beauty and personal care products, including color cosmetics, hair color, hair care and hair treatments, as well as beauty tools, men’s grooming products, anti-perspirant deodorants, fragrances, skincare and other beauty care products. The company has market cap of $1.20 billion.

The stock of Cellectis SA (ADR) (NASDAQ:CLLS) is a huge mover today! About 70,333 shares traded. Cellectis SA (ADR) (NASDAQ:CLLS) has declined 17.09% since July 10, 2016 and is downtrending. It has underperformed by 33.79% the S&P500.The move comes after 6 months positive chart setup for the $934.84M company. It was reported on Jul, 10 by Barchart.com. We have $27.78 PT which if reached, will make NASDAQ:CLLS worth $46.74 million more.

Mittleman Brothers Llc holds 30.71% of its portfolio in Revlon Inc for 2.13 million shares. Harvey Partners Llc owns 63,900 shares or 1.96% of their US portfolio. Moreover, Zebra Capital Management Llc has 0.4% invested in the company for 45,753 shares. The Pennsylvania-based Stoneridge Investment Partners Llc has invested 0.25% in the stock. Graham Capital Management L.P., a Connecticut-based fund reported 36,425 shares.

Since January 1, 0001, it had 6 buys, and 0 selling transactions for $41.04 million activity.

About 24,014 shares traded. Revlon Inc (REV) has declined 37.40% since July 10, 2016 and is downtrending. It has underperformed by 54.10% the S&P500.

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The company has market cap of $934.84 million. The Firm specializes in the research, development and commercialization of rational genome engineering technologies. It currently has negative earnings. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.